ISCT 2021 Industry Symposium

Translating Cellular Therapies from Bench to Clinic –

The Critical Role of GMP-compliant, Scalable Cell Engineering Technology

Executive Summary

Wednesday, May 26th 2021

Increasingly sophisticated approaches to cellular engineering, including CRISPR-mediated gene editing and expression of disease-targeting receptors, require corresponding advances in cellular delivery technologies. Aside from the high manufacturing costs of viral vectors, demand for non-viral methods is driven by the diversity of cell types (e.g,, T cells, NK cells, stem cells) and loading agents (e.g., RNPs, mRNA, transposons) that are central to many engineered cellular therapies. Moreover, aggressive development timelines combined with strict standards for safety and therapeutic potency create a need for cell modification protocols that translate seamlessly from the research lab into the clinic, accommodating a broad range of processing scales without compromising cell viability or loading efficiency. This Industry Symposium brings together leading researchers and clinicians to discuss their experiences with translating and scaling non-viral approaches to engineered cellular therapies.


James Brady, PhD, MBA

VP, Technical Applications & Customer Suppor


Babak Moghimi MD

Assistant Professor of Pediatrics
Transplant and Cell Therapy
Children Hospital of Los Angeles (CHLA)
Keck School of Medicine, USC

Angelo A. Cardoso, M.D., Ph.D.

City of Hope
Laboratory for Cellular Medicine

Celine Mahieu

University of California in San Francisco
Doctoral student

Melissa Berrien-Elliott, Ph.D.

Instructor in Medicine
Washington University School of Medicine,
Division of Oncology

Visit our posters in the poster hall

Maxcyte Flow Electroporation Technology: A Safe, Reliable and Effective Method for Engineering CAR T Cells

Efficient and Scalable T Cell Engineering for Advancing Cancer Immunotherapy of Hepatocellular Carcinoma by a cGmp-Compliant Non-Viral Cell Engineering Platform